| April 19, 2012 | ISSUE NUMBER 247 VOL 8 |
|
Special Feature
Outlook Uncertain for Pharma and Biotech Deals
Following a 'turbulent' 2011, Peter Young looks what lies ahead in pharma and biotech's M&A space in 2012 and beyond ...Read more
Patient Adherence
Cracking the Adherence Nut: Drug Delivery
Chris Evans and Ed Geiselhart consider the importance of drug delivery systems in facilitating patient adherence ...Read More
Strategy
Crossing the M&A Minefield
Whether it's M&A activity or a carve-out, there are a number of regulatory and technical issues routinely left on the back burner until a deal is closed and the transition begins. Jim Bedford offers advice on how to navigate these complexities ...Read More
Patient Access
How Can Industry Help in Expediting Access?
John Lagus and Kelly Feam outline how managed access programs can provide a route to obtain innovative drugs prior to approval or launch
...Read more
|
|
|
 // John Lechleiter, Chairman, President and Chief Executive of Lilly has been elected Chairman of the Pharmaceutical Research and Manufacturers of America (PhRMA). // Jim Lang was appointed President of the Market Access Business Unit of research and advisory firm Decision Resources Group (Burlington, MA and Mt. Olive, NJ). // Kantar Health (New York, NY) named Stephen Potts to lead its Global Marketing Insights practice. Mr Potts will also continue in his current role as Kantar Health's Managing Director of Asia Pacific, Middle East and Africa (APMEA). The company also named Richard Goosey as Senior Director, Advanced Methods, based in the UK. // MediMedia Health (Yardley, PA) appointed Phil Deschamps as President and CEO.
|
|
|
|
Advertisement
Utilization of Rasch Measurement Models for Assessing Validity: A Mixed Methods Approach
On-Demand Webcast
 Click here |
|
|
|
|
|
 |
|
|
 |
 |
|
 |
What is the most pressing concern facing your company?
|
|
|
|
